Two new Alzheimer’s drugs that can slow the disease will not be available on the NHS, after the National Institute for Health and Care Excellence rejected them for a third time. In final draft guidance published on 19 June 2025, NICE said donanemab, sold as Kisunla by Eli Lilly, and lecanemab, sold as Leqembi by Eisai, should not be provided on the NHS in England and Wales. Both drugs are the first treatments shown to slow early Alzheimer’s by clearing amyloid protein from the brain, delaying progression from mild to moderate disease by about four to six months. Both are licensed in Britain by the medicines regulator, the MHRA, lecanemab since August 2024 and donanemab since October 2024. NICE accepted that even a small slowing of the disease would matter to patients and carers, giving more time for independence, driving and social life. But its committee concluded the benefit was too small to justify the cost and the resources needed: fortnightly infusions for lecanemab and monthly infusions for donanemab, regular brain scans and genetic testing, and monitoring for swelling and bleeding in the brain. Both manufacturers said they would appeal.
What the Evidence Shows
The decision has disappointed families who hoped the drugs would be a turning point, but it also reflects a genuine dilemma. The NHS has a fixed budget, and money spent on these drugs would be money not spent on other care, including the diagnosis and support services that people with dementia need today. The drugs are available privately and in some other countries, including the United States, where they are covered by Medicare for eligible patients, which has created a two-tier picture that many find uncomfortable. Researchers say better drugs are in development, and that the first amyloid-clearing medicines have proved the disease can be slowed, which was not known a decade ago. For now, the best advice remains the everyday steps that protect the brain: staying active, controlling blood pressure, treating hearing loss and keeping socially connected. Reporting and analysis from sources such as National Institutes of Health track the same developments, and specialists following Alzheimer’s drugs decision say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a health system trying to move from treating illness late to preventing it early, against budgets that reward the opposite. Evidence around Alzheimer’s drugs decision is being weighed by guideline committees that ask two questions in order: does it work, and can ordinary services actually deliver it at scale. Many good ideas pass the first test and stall on the second.
What Happens Next
What happens next for Alzheimer’s drugs decision depends on the slow machinery of guidelines, funding and training catching up with the evidence. Patients asking about it today should expect honest answers that include uncertainty, and clinicians say a service that explains what is not yet known earns more trust than one that oversells. The research pipeline, at least, is moving in the right direction. You can follow related developments in our coverage of health.
None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.